Why MACI Suits Some Patients but Not Others

Whether MACI is the right operation is rarely a straightforward yes or no. It is a two-stage, cell-based procedure designed for a specific and fairly narrow clinical profile — and when it is matched to the right patient, published series report meaningful, durable improvements in pain and function. When it is not, the outcome suffers regardless of how well the surgery itself is performed. Candidate selection, in other words, is at least as important as surgical technique.

Three interlocking dimensions shape that decision: the characteristics of the cartilage defect itself, the patient's age and biological capacity for repair, and the practical ability to commit to the full treatment process. All three must align.

That process is worth understanding before the criteria are examined in detail. MACI involves two separate procedures: a first-stage arthroscopic biopsy to harvest healthy chondrocytes, a laboratory phase during which those cells are cultured and seeded onto a collagen membrane scaffold, and then a second-stage open implantation — followed by a rehabilitation programme that extends beyond nine months. A patient who is eligible on paper but unable to sustain that commitment is not, in practice, a good candidate.

Defect Grade, Size and Location

Three cartilage characteristics determine whether a defect is technically treatable with MACI: its severity, its size, and where in the knee it sits.

Severity — full-thickness damage only

MACI addresses defects graded III or IV on the ICRS (International Cartilage Repair Society) scale — damage that penetrates more than halfway through the cartilage layer, or reaches all the way down to the bone beneath. A useful shorthand is the 'pothole' picture: the surface has broken through rather than simply thinned. Just as importantly, the defect must be symptomatic — causing pain, swelling, or mechanical symptoms — and focal, meaning the surrounding cartilage border is intact. Incidental damage found on a scan, or widespread thinning across the joint surface, does not meet these criteria.

Size — the 3–10 cm² range

Defect area is where the evidence is most precise. The SUMMIT trial, comparing MACI with microfracture, demonstrated statistically significant gains in KOOS pain and function scores at both two and five years for defects measuring 3 cm² or larger. This defines the core indication. Below 2 cm², other techniques — osteochondral autograft transfer (OATS) among them — tend to produce equivalent results with less procedural complexity, so MACI is rarely indicated at that size. Microfracture, once the default for small defects, carries a recognised risk of fibrocartilage breakdown at two to three years and is in declining use as a standalone repair strategy.

Registry data from 2,690 patients treated across Europe and Australia add important real-world context: 70% of defects fell in the 3–10 cm² range, with a mean of 5.64 cm² — meaningfully larger than the 4.89 cm² mean reported in clinical trials. That gap reflects the reality that surgeons in practice are treating more complex cases than those enrolled in controlled studies.

Bone involvement and location

Where bone loss underlies the cartilage defect — specifically a cavitary depth exceeding 8 mm — this is also an accepted indication. Treatable sites include the medial and lateral femoral condyles (which account for more than half of all cases), the patella, and the trochlea. MACI's collagen membrane design allows it to cover patellofemoral lesions and irregular, uncontained defects that earlier ACI techniques could not reliably address.

Age Range and Biological Readiness

Formal eligibility begins with age. The FDA has approved MACI for patients aged 18 to 55; safety and effectiveness outside that window have not been formally established, and the label is clear on this point.

In practice, however, specialist centres concentrate on a narrower band. Patients under 40 are considered the strongest candidates, for a straightforward biological reason: chondrocyte activity — the cells' capacity to proliferate, integrate, and lay down repair tissue — is greatest in younger adults and diminishes progressively with age. Selection does extend to around 45 in carefully assessed individuals, but the biological case becomes more nuanced beyond that point. Registry data from 2,690 MACI recipients across Europe and Australia reflect this clinical concentration: the mean patient age was 33.7 years, and the male-to-female ratio was approximately two to one — figures that align closely with the active adult demographic for whom the procedure was designed.

The 55-year ceiling deserves a specific note. It is a regulatory boundary, set by the age range of patients enrolled in the trials on which FDA approval was based — not a hard biological cliff. Some specialist centres do assess and treat selected patients beyond 55 on an individual basis, outside the formal indication. That distinction matters: it means the ceiling is a statement about the evidence, not a universal rule about what is biologically possible.

In the UK, NICE Technology Appraisal TA477 (2017) adds a further structural gate: patients must have had no previous articular cartilage repair surgery in the same knee. This criterion reflects both the biological complexity of revision cases — where the repair environment is compromised — and the economic calculation that underpins NHS funding decisions. It is not a bureaucratic formality; prior marrow-stimulation procedures in particular are associated with higher failure rates in subsequent cell-based repair.

Fitness, BMI, Smoking and Commitment to Rehabilitation

Physical fitness and life capacity are the third dimension of candidacy — less visible than defect grade or age, but no less relevant to whether MACI succeeds.

Body weight, smoking, and healing biology

Mayo Clinic's candidacy criteria include a healthy, athletic BMI and non-smoking status. Neither is an FDA-mandated requirement, and both are better understood as clinical reasoning than regulatory rule: cartilage graft integration depends on adequate soft-tissue perfusion and controlled mechanical loading, and excess body weight compromises both. Nicotine is a vasoconstrictor that measurably impairs tissue perfusion and the healing cascade; patients who smoke are routinely advised to stop before proceeding. These thresholds are centre-specific rather than universal, and a consultant will weigh them in the context of the individual — they are not automatic disqualifying gates, but they are meaningful factors in any honest candidacy assessment.

The nine-month rehabilitation and procedural gap

Candidates face two separate procedures with several weeks between them — time that demands concrete planning around work, caring responsibilities, and daily life. After implantation, a structured rehabilitation programme of nine months or more begins. Weight-bearing is restricted early and reintroduced in staged increments under a protocol-driven approach; return to full sport may extend beyond a year for certain activities.

The procedural burden is front-loaded, but the rehabilitative commitment is the longer test. A patient with an anatomically ideal defect who genuinely cannot sustain nine months of graduated loading — or who cannot protect the graft during its early integration phase — is not a strong candidate, not because the joint fails the clinical criteria, but because the conditions for successful healing are not in place. Motivation and life circumstances, in this respect, are genuine clinical variables.

Conditions That Rule MACI Out

Several conditions make MACI clinically inappropriate regardless of defect size or age. Understanding these exclusions helps patients arrive at a consultation better prepared.

Absolute contraindications

• Diffuse or multi-compartment osteoarthritis. MACI is designed for focal, contained damage. Where degeneration has spread across the joint, focal cartilage repair cannot address the underlying problem, and the conversation shifts to joint preservation or replacement.
• Inflammatory arthritis, including rheumatoid arthritis. Systemic joint disease creates a biological environment actively hostile to cartilage graft survival; focal repair is not appropriate while inflammatory disease remains active or inadequately controlled.
• Active joint infection. An infected joint cannot be operated upon for restorative purposes until the infection is fully resolved — this is an unconditional bar.
• Pregnancy. The procedure and its associated treatment protocols are contraindicated.
• Allergy to porcine-derived collagen or to specific antibiotics used during the cell expansion process.

Correctable mechanical factors — not permanent bars

• Ligament instability or severe malalignment. Neither rules MACI out permanently. Both must be addressed before or concurrently with implantation — through ligament reconstruction or corrective osteotomy — because an unstable or mechanically loaded graft will not integrate reliably. Concomitant surgery is accepted practice, and many centres perform both procedures at the same time.

These exclusions exist to protect patients: implanting cultured cells into a joint environment that cannot support their integration exposes someone to a demanding two-stage procedure with no realistic prospect of benefit.

Getting an Accurate Assessment at MSK Doctors

The criteria covered across this article — defect grade and containment, defect size, biological age, physical fitness, and mechanical alignment — interact in ways that no checklist can resolve independently. Whether a specific lesion meets containment thresholds, whether the surrounding joint is sufficiently stable, and whether a patient's circumstances genuinely support a nine-month rehabilitation commitment are questions that require imaging and a structured specialist assessment.

At MSK Doctors, that process covers defect morphology, bone involvement, joint stability, and rehabilitation capacity as part of a single consultative review — with no GP referral required. Imaging is central to the decision: the Sleaford clinic (Lincolnshire, NG34) has an on-site Open MRI scanner, and the Grantham centre (NG31) provides consultation and diagnostics. Where alignment or loading patterns need objective quantification alongside imaging, MAI Motion® biomechanical assessment can add measurable data to the clinical picture.

The consultation will not always conclude that MACI is the right pathway. Depending on defect size, prior surgery history, or the patient's age and biology, alternatives — AMIC, OATS, a ChondroFiller injection, or osteochondral allograft — may suit the situation better; a thorough candidacy review considers all of them proportionately. Patients based in London can access specialist cartilage assessment through the London Cartilage Clinic.

Appointments at MSK Doctors are available without referral at mskdoctors.com.

1. [1] Patients Scheduled for Chondrocyte Implantation Treatment with MACI Have Larger Defects than Those Enrolled in Clinical Trials – PMC. (2015). https://pmc.ncbi.nlm.nih.gov/articles/PMC4797242/ https://pmc.ncbi.nlm.nih.gov/articles/PMC4797242/
2. [2] Prospective Clinical and Radiological Follow-Up Beyond 10 Years in Patients Undergoing MACI in the Patellofemoral Joint. (2024). https://doi.org/10.1177/2325967124s00196 https://doi.org/10.1177/2325967124s00196